Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

Lung Cancer

Volumn 65, Issue 3, 2009, Pages 377-382

  Lee, Hyun Woo ^a   Choi, Yong Won ^a   Han, Jae Ho ^a   Kim, Jang Hee ^a   Jung, Jae Ho ^a   Jeong, Seong Hyun ^a   Kang, Seok Yun ^a   Choi, Jin Hyuk ^a   Oh, Young Taek ^a   Park, Kwang Joo ^a   Hwang, Sung Chul ^a   Sheen, Seung Soo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chemotherapy; ERCC1; Lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER STAGING; CONTROLLED STUDY; DISEASE CONTROL; ENDOSCOPIC BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THORACOSCOPY; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651240812     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.12.005     Document Type: Article

References (30)

1. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
2. Shin H.-R., Jung K.-W., Won Y.-J., and Park J.-G. 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 36 (2004) 103
3. Ramalingam S., and Belani C.P. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 31 (2004) 68-74
4. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
6. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007) 317-323
7. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
8. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13 (2006) 1378-1386
9. Reardon J.T., Vaisman A., Chaney S.G., and Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59 (1999) 3968-3971
10. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
11. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11 (2005) 6100-6102
12. Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F., et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24 (2004) 5776-5787
13. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331 (2005) 868-880
14. Rosell R., Taron M., Ariza A., Barnadas A., Mate J.L., Reguart N., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31 (2004) 20-27
15. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Kaplan E., and Meier P. Non-parametric estimations from incomplete observations. J Am Statistical Assoc 53 (1958) 457-481
18. Cox D.R. Regression model and life-tables. J Roy Statist Soc Ser 34 (1972) 187-220
19. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., and Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11 (2005) 3974-3986
20. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18 (2001) 705-719
21. Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 19 (2002) 134-140
22. Solan M.J., and Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21 (2003) 64-73
23. Lara Jr. P.N., Redman M.W., Kelly K., Edelman M.J., Williamson S.K., Crowley J.J., et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 26 (2008) 463-467
24. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., and Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 (2005) 211-219
25. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98 (2007) 1336-1343
26. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
27. Lee K.H., Min H.S., Han S.W., Oh D.Y., Lee S.H., Kim D.W., et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60 (2008) 401-407
28. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
29. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
30. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325